Evidence Hub

Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone

Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L, ZA-203 Clinical Study Group

Fertility and sterility, 2014

Abstract

OBJECTIVE: To determine the effect of enclomiphene citrate in men with secondary hypogonadism.

DESIGN: Phase II clinical trial.

SETTING: Community dwelling men making visits to physician offices.

PATIENT(S): Men with secondary hypogonadism.

INTERVENTION(S): Oral administration of enclomiphene citrate or 1% topical T gel.

MAIN OUTCOME MEASURE(S): Luteinizing hormone, FSH, T, and semen analysis.

RESULT(S): Treatment with enclomiphene citrate resulted in increased morning serum T, E2, and LH levels similar to those obtained with a topical T gel in men with secondary hypogonadism. Follicle-stimulating hormone and LH were increased with enclomiphene, and sperm counts were conserved.

CONCLUSION(S): Enclomiphene citrate reverses the two hallmarks of secondary hypogonadism, namely, low serum total T and low or inappropriately normal LH while preserving sperm production.

CLINICAL TRIAL REGISTRATION NUMBER: NCT01270841 (ClinicalTrials.gov Identifier NCT01270841).

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free